

## Correlation between Genotype and Phenotype characteristics in Children with Congenital Hyperinsulinism (CHI) in a specialist centre.

Laura Bosch<sup>1</sup>, Jasmina Mohammad<sup>1</sup>, Antonia Dastamani<sup>1</sup>, Clare Gilbert<sup>1</sup>, Kate Morgan<sup>1</sup>, Jayne Houghton<sup>2</sup>, Sian Ellard<sup>2</sup>, Sarah Flanagan<sup>2</sup>, Pratik Shah<sup>1,3</sup>

<sup>1</sup>Department of Paediatric Endocrinology, Great Ormond Street Hospital, London

<sup>2</sup>Genetic Laboratory, Royal Devon & Exeter NHS Foundation Trust, University of Exeter Medical School, Exeter, UK.

<sup>3</sup>Genetics and Epigenetics in Health and Disease Section, Genetics and Genomics Medicine Program, UCL GOS Institute of Child Health, London, UK

### Introduction and Aim:

Congenital hyperinsulinism (CHI) is the most common cause of hypoglycaemia in early infancy and represents a heterogeneous disorder with respect to clinical presentation, histology and genetics. The aim of our study is to review correlation between genotype and phenotypic characteristics of children with CHI.

### Methods:

Retrospective review of CHI patients with positive genetics during the last 8 years in a specialist referral centre.

### Results:

Total of 71 children have so far been identified with positive genetic mutation (40 males).

- The median age of presentation with hypoglycaemia was 0-2 days in all mutations except *GLUD1* (259.5 days).
- The median birthweight was significantly higher in children with  $K_{ATP}$  channel mutations than in *GLUD1* and *GCK*.

### GENETICS

- The majority had  $K_{ATP}$  channel (*ABCC8/KCNJ11*) mutation (n=55).
  - 15 had compound heterozygous/homozygous  $K_{ATP}$  channel mutation.
  - 30 had paternal inherited  $K_{ATP}$  mutation.
  - 10 had maternal inherited  $K_{ATP}$  mutation
- The rest were 9 *HNF4a*, 4 *PMM2*, 2 *GLUD1* and 1 *GCK* mutation respectively.

### DIAZOXIDE RESPONSIVENESS

- 4 (26.7%) compound heterozygous  $K_{ATP}$
- 7 (23.3%) paternal inherited
- 7 (70%) maternal inherited  $K_{ATP}$  channel mutation.
- 9 (88.9%) with *HNF4a*
- 2 (100%) with *GLUD1*
- 1 (25%) with *PMM2*

### PARTIAL RESPONSE TO DIAZOXIDE

- 2 (13.3%) compound heterozygous
- 3 (10%) paternal inherited
- 1 (10%) with maternal inherited  $K_{ATP}$  channel.

### OTHER MEDICAL THERAPIES

- 3 (75%) with *PMM2* mutation had good response to Nifedipine when used in conjunction with Diazoxide.
- 12 children with  $K_{ATP}$  channel mutation were managed on octreotide, sirolimus and Lanreotide.

### NATURAL REMISSION

- 1 compound  $K_{ATP}$  (1.56 years)
- 5 (18.5%) in paternal  $K_{ATP}$  (median age 2.19 years)
- 5 (50%) in maternal  $K_{ATP}$  (median age 0.33 years)
- 1 in *HNF4a* (0.66 years)

### PANCREATECTOMY

- 21 patients (29.6%) underwent pancreatectomy:
  - 16 partial pancreatectomy for focal CHI
  - 5 subtotal pancreatectomy for diffuse form of CHI.

### Conclusion:

There is no significant difference noted in age of presentation amongst all except *GLUD1* mutation which presents much later in life. Most children with  $K_{ATP}$  channel mutation require frequent feeds with multiple medications to manage severe form of CHI. Knowledge of genotype might help to determine pharmacotherapy. The odds of being fully responsive to diazoxide was greater in patients with maternal  $K_{ATP}$  channel than in homozygous, compound heterozygous and paternal inherited  $K_{ATP}$  channel mutation respectively.